The Claim
Plasma levels of Th17-associated cytokines (IL-17a, IL-22, IL-23, IL-6, IL-10) do not differ significantly between patients with Hashimoto’s thyroiditis, patients with Graves’ disease, and healthy controls, indicating that systemic circulating levels of these cytokines are not reliable biomarkers for distinguishing between these autoimmune thyroid conditions or from non-autoimmune states.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Measurements of five specific immune proteins in the blood are not consistently different between people with Hashimoto’s thyroiditis, Graves’ disease, and people without autoimmune thyroid disease, meaning these proteins cannot be used to tell these conditions apart from each other or from healthy states.
See the scientific wording
Plasma levels of Th17-associated cytokines (IL-17a, IL-22, IL-23, IL-6, IL-10) do not differ significantly between patients with Hashimoto’s thyroiditis, Graves’ disease, and healthy controls, indicating that systemic circulating levels of these cytokines are not reliable biomarkers for distinguishing between these autoimmune thyroid conditions or from non-autoimmune states.
What the research says
1 studyStudy: Plasma levels of Th17‐associated cytokines and selenium status in autoimmune thyroid diseases
Scientists checked if certain immune chemicals in the blood could tell apart people with two different thyroid diseases from healthy people. They found these chemicals were about the same in all three groups, so they can’t be used as a reliable test to tell who has which condition.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.